Polymer–drug conjugate therapeutics: advances, insights and prospects

[1]  K. S. Dalal,et al.  Oncology drugs. , 2019, Nursing.

[2]  R. Echols,et al.  in a Phase 2 Study , 2019 .

[3]  Hua Lu,et al.  Polysarcosine as an Alternative to PEG for Therapeutic Protein Conjugation. , 2018, Bioconjugate chemistry.

[4]  Jun Ling,et al.  Polysarcosine-containing copolymers: Synthesis, characterization, self-assembly, and applications , 2018, Progress in Polymer Science.

[5]  M. Grinstaff,et al.  Reinforcement of polymeric nanoassemblies for ultra-high drug loadings, modulation of stiffness and release kinetics, and sustained therapeutic efficacy. , 2018, Nanoscale.

[6]  M. Vicent,et al.  Anticancer Activity Driven by Drug Linker Modification in a Polyglutamic Acid‐Based Combination‐Drug Conjugate , 2018 .

[7]  K. Larimore,et al.  Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). , 2018, Molecular genetics and metabolism.

[8]  B. Hendriks,et al.  Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines , 2018, Theranostics.

[9]  W. Dehaan,et al.  P109 Clinical development of a novel strategy to mitigate biologic immunogenicity: monthly dosing of a pegylated uricase with SVP-R enables sustained reduction of serum uric acid (SUA) levels by mitigating formation of anti-drug antibodies (ADAS) , 2018 .

[10]  Lei Zheng,et al.  HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Leff,et al.  A first-in-man phase 1 trial for long-acting TransCon Growth Hormone. , 2017, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[12]  A. Skerra,et al.  Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action. , 2017, Bioorganic & medicinal chemistry.

[13]  L. Webster,et al.  Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone , 2017, Pain medicine.

[14]  J. Bowser,et al.  The hypoxia-adenosine link during inflammation. , 2017, Journal of applied physiology.

[15]  E. Perez,et al.  Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial , 2017, Breast Cancer Research and Treatment.

[16]  Daniel H. Foil,et al.  Synthesis of poly(1,2-glycerol carbonate)–paclitaxel conjugates and their utility as a single high-dose replacement for multi-dose treatment regimens in peritoneal cancer† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03501b , 2017, Chemical science.

[17]  W. Rubas,et al.  NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[18]  D. Karpf,et al.  The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency , 2017, Endocrine connections.

[19]  Philip S Low,et al.  Ligand-Targeted Drug Delivery. , 2017, Chemical reviews.

[20]  Pascal Deschatelets,et al.  APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria , 2017 .

[21]  J. Kopeček,et al.  The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment. , 2017, Current opinion in colloid & interface science.

[22]  R. Duncan.  Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century , 2017, Journal of drug targeting.

[23]  M. Urowitz,et al.  Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles , 2017, Annals of the rheumatic diseases.

[24]  W. Rubas,et al.  Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy , 2017, PloS one.

[25]  E. Perez,et al.  Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial , 2017, Breast Cancer Research and Treatment.

[26]  A. Chilkoti,et al.  From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers. , 2017, Angewandte Chemie.

[27]  A. Rawal,et al.  The Effect of Drug Loading on Micelle Properties: Solid-State NMR as a Tool to Gain Structural Insight. , 2017, Angewandte Chemie.

[28]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[29]  Karen Campbell,et al.  64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[30]  R. Harniman,et al.  Scalable and uniform 1D nanoparticles by synchronous polymerization, crystallization and self-assembly. , 2017, Nature chemistry.

[31]  R. Zhang,et al.  Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts. , 2017, Molecular pharmaceutics.

[32]  R. Korn,et al.  Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.

[33]  Honggang Cui,et al.  Peptide–drug conjugates as effective prodrug strategies for targeted delivery , 2017, Advanced drug delivery reviews.

[34]  Gangyi Yang,et al.  Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients , 2017, Journal of diabetes.

[35]  R. Greil,et al.  Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study , 2017, Leukemia.

[36]  P. Giangrande,et al.  Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[37]  docetaxel positive phase 1 results ; phase 2 commences , 2017 .

[38]  B. Neuschwander‐Tetri,et al.  BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study , 2017 .

[39]  S. Beck,et al.  Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial , 2017, JAMA oncology.

[40]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[41]  H. Mukai,et al.  A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors , 2017, Investigational New Drugs.

[42]  Shaoyi Jiang,et al.  Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[43]  F. Danhier,et al.  To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[44]  S. Nilsson,et al.  Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study. , 2016, Anticancer research.

[45]  V. Schellenberger,et al.  Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Kimberly S Butler,et al.  Ligand-targeted theranostic nanomedicines against cancer. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[47]  P. Ott,et al.  Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  F. Wurm,et al.  Degradable Polyphosphoester-Protein Conjugates: "PPEylation" of Proteins. , 2016, Biomacromolecules.

[49]  S. van Calenbergh,et al.  Well-Defined Polymer-Paclitaxel Prodrugs by a Grafting-from-Drug Approach. , 2016, Angewandte Chemie.

[50]  Guilin Wang,et al.  In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Fabian Kiessling,et al.  Cancer nanomedicine: Is targeting our target? , 2016, Nature reviews. Materials.

[52]  Zhonggui He,et al.  Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy. , 2016, Nano letters.

[53]  W. Cefalu,et al.  Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes , 2016, Diabetes Care.

[54]  Ryan M. Pearson,et al.  Tuning the Selectivity of Dendron Micelles Through Variations of the Poly(ethylene glycol) Corona. , 2016, ACS nano.

[55]  P. Leung,et al.  Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus , 2016, Medicinal research reviews.

[56]  Jun Wang,et al.  Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. , 2016, ACS nano.

[57]  L. Gold,et al.  Fit for the Eye: Aptamers in Ocular Disorders , 2016, Nucleic acid therapeutics.

[58]  E. Dees,et al.  A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors. , 2016 .

[59]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[60]  K. Ulbrich,et al.  Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. , 2016, Chemical reviews.

[61]  M. Dandri,et al.  Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. , 2016, Journal of hepatology.

[62]  Jun Wang,et al.  Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy , 2016, Proceedings of the National Academy of Sciences.

[63]  Yanyan Wang,et al.  Environmentally Benign CO2-Based Copolymers: Degradable Polycarbonates Derived from Dihydroxybutyric Acid and Their Platinum-Polymer Conjugates. , 2016, Journal of the American Chemical Society.

[64]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[65]  Thomas Lorson,et al.  Peptoids and Polypeptoids at the Frontier of Supra- and Macromolecular Engineering. , 2016, Chemical reviews.

[66]  Yaping Li,et al.  Intracellularly Acid-Switchable Multifunctional Micelles for Combinational Photo/Chemotherapy of the Drug-Resistant Tumor. , 2016, ACS nano.

[67]  P. Turecek,et al.  PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. , 2016, Journal of pharmaceutical sciences.

[68]  M. Addepalli,et al.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.

[69]  Yue Jiang,et al.  pH-responsive polymer-drug conjugates: Design and progress. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[70]  D. Dearnaley,et al.  Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial (CRUK/06/016). , 2016 .

[71]  D. Eliott,et al.  A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. , 2016, Ophthalmology.

[72]  K. Wooley,et al.  Functionalizable Hydrophilic Polycarbonate, Poly(5-methyl-5-(2-hydroxypropyl)aminocarbonyl-1,3-dioxan-2-one), Designed as a Degradable Alternative for PHPMA and PEG , 2015 .

[73]  Amy M. Holthaus,et al.  Evaluation of Enhanced in Vitro Plasma Stability of a Novel Long Acting Recombinant FVIIIFc-VWF-XTEN Fusion Protein , 2015 .

[74]  Scott T. Miller,et al.  TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia , 2015 .

[75]  Hongyan Xu,et al.  Targeted polymer-drug conjugates: Current progress and future perspective. , 2015, Colloids and surfaces. B, Biointerfaces.

[76]  Ashley M. Laughney,et al.  Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.

[77]  F. Janku,et al.  CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study , 2015, Journal of Immunotherapy for Cancer.

[78]  E. Perez,et al.  Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[79]  M. Swierczewska,et al.  What is the future of PEGylated therapies? , 2015, Expert opinion on emerging drugs.

[80]  G. Georgiou,et al.  Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. , 2015, Human molecular genetics.

[81]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[82]  R. Hoogenboom,et al.  Transiently responsive protein-polymer conjugates via a 'grafting-from' RAFT approach for intracellular co-delivery of proteins and immune-modulators. , 2015, Chemical communications.

[83]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[84]  S. H. van der Burg,et al.  A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer , 2015, Oncotarget.

[85]  B. Katzenellenbogen,et al.  Ligand Accessibility and Bioactivity of a Hormone-Dendrimer Conjugate Depend on pH and pH History. , 2015, Journal of the American Chemical Society.

[86]  Jonathan R. McDaniel,et al.  A Paclitaxel-Loaded Recombinant Polypeptide Nanoparticle Outperforms Abraxane in Multiple Murine Cancer Models , 2015, Nature Communications.

[87]  D. Arnold,et al.  Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE , 2015, Multiple sclerosis.

[88]  S. Dhar,et al.  A Nanoparticle Cocktail: Temporal Release of Predefined Drug Combinations. , 2015, Journal of the American Chemical Society.

[89]  Jean Felix Mukerabigwi,et al.  Precise Ratiometric Control of Dual Drugs through a Single Macromolecule for Combination Therapy. , 2015, Molecular pharmaceutics.

[90]  Andreas Kjær,et al.  Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. , 2015, ACS nano.

[91]  J. Kopeček,et al.  Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer. , 2015, Journal of the American Chemical Society.

[92]  B. Boyce,et al.  Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. , 2015, Acta dermato-venereologica.

[93]  P. Kearns,et al.  Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. , 2015, Blood.

[94]  Xiaoli Wei,et al.  A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. , 2015, Angewandte Chemie.

[95]  A. J. van der Lely,et al.  Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[96]  Karly P Garnock-jones.  Naloxegol: A Review of Its Use in Patients with Opioid-Induced Constipation , 2015, Drugs.

[97]  David R. Liu,et al.  Targeted antithrombotic protein micelles. , 2015, Angewandte Chemie.

[98]  Carolyn R Bertozzi,et al.  Formylglycine, a post-translationally generated residue with unique catalytic capabilities and biotechnology applications. , 2015, ACS chemical biology.

[99]  Xianglong Hu,et al.  Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals. , 2015, Journal of the American Chemical Society.

[100]  Jing Wang,et al.  Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles. , 2015, Angewandte Chemie.

[101]  W. Hennink,et al.  Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. , 2015, Biomaterials.

[102]  N. Masuda,et al.  Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy , 2015, Supportive Care in Cancer.

[103]  M. Birrer,et al.  Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer , 2014, Clinical Cancer Research.

[104]  M. Loh,et al.  Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Craig J. Hawker,et al.  Synthetic Aptamer-Polymer Hybrid Constructs for Programmed Drug Delivery into Specific Target Cells , 2014, Journal of the American Chemical Society.

[106]  Zhuxian Zhou,et al.  Molecularly precise dendrimer-drug conjugates with tunable drug release for cancer therapy. , 2014, Angewandte Chemie.

[107]  M. Klein,et al.  Mimicking biological membranes with programmable glycan ligands self-assembled from amphiphilic Janus glycodendrimers. , 2014, Angewandte Chemie.

[108]  S. Prabhu,et al.  Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? , 2014, Drug discovery today.

[109]  Xiao-Jun Ma,et al.  Extended peginterferon alfa‐2a (Pegasys) therapy in Chinese patients with HBeAg‐negative chronic hepatitis B , 2014, Journal of medical virology.

[110]  En-Wei Lin,et al.  Therapeutic protein-polymer conjugates: advancing beyond PEGylation. , 2014, Journal of the American Chemical Society.

[111]  Kazunori Kataoka,et al.  Progress of drug-loaded polymeric micelles into clinical studies. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[112]  U. Hoch,et al.  Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models , 2014, Cancer Chemotherapy and Pharmacology.

[113]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[114]  R. Zhang,et al.  Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates , 2014, Proceedings of the National Academy of Sciences.

[115]  X. Li,et al.  PEGylated PAMAM dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy. , 2014, Biomaterials.

[116]  H. Misra,et al.  PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial. , 2014, Artificial organs.

[117]  Simon R. Cherry,et al.  A Smart and Versatile Theranostic Nanomedicine Platform based on Nanoporphyrin , 2014, Nature Communications.

[118]  Bin Liu,et al.  Conjugated-polyelectrolyte-based polyprodrug: targeted and image-guided photodynamic and chemotherapy with on-demand drug release upon irradiation with a single light source. , 2014, Angewandte Chemie.

[119]  Allie C. Obermeyer,et al.  N-Terminal Modification of Proteins with o-Aminophenols , 2014, Journal of the American Chemical Society.

[120]  K. Kataoka,et al.  Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) , 2014, International journal of nanomedicine.

[121]  S. Fukushima,et al.  Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor. , 2014, ACS nano.

[122]  D. Owen,et al.  Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[123]  L. Medina,et al.  High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin , 2014, Cancer Chemotherapy and Pharmacology.

[124]  Byung-Heon Lee,et al.  Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy , 2014, Nature Communications.

[125]  Jonathan R. McDaniel,et al.  Rational Design of “Heat Seeking” Drug Loaded Polypeptide Nanoparticles That Thermally Target Solid Tumors , 2014, Nano letters.

[126]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[127]  Sang Cheon Lee,et al.  Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers. , 2014, ACS nano.

[128]  D. Santi,et al.  Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation. , 2014, Journal of medicinal chemistry.

[129]  S. Svenson.  What nanomedicine in the clinic right now really forms nanoparticles? , 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[130]  M. Vicent,et al.  Peptide-Based Polymer Therapeutics , 2014 .

[131]  W. Driessen,et al.  Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. , 2014, Journal of the American Chemical Society.

[132]  F. Fares,et al.  Benzene-Poly-Carboxylic Acid Complex, a Novel Anti-Cancer Agent Induces Apoptosis in Human Breast Cancer Cells , 2014, PloS one.

[133]  Wojciech G. Lesniak,et al.  Dendrimer Brain Uptake and Targeted Therapy for Brain Injury in a Large Animal Model of Hypothermic Circulatory Arrest , 2014, ACS nano.

[134]  J. Kopeček,et al.  Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis. , 2014, ACS nano.

[135]  K. Ulbrich,et al.  Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. , 2014, ACS nano.

[136]  G. Pasut.  Polymers for Protein Conjugation , 2014 .

[137]  A. Adams,et al.  Inventing new medicines: The FGF21 story☆ , 2013, Molecular metabolism.

[138]  Baran D. Sumer,et al.  A Broad Nanoparticle-Based Strategy for Tumor Imaging by Nonlinear Amplification of Microenvironment Signals , 2013, Nature materials.

[139]  D. M. van der Heijde,et al.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) , 2013, Annals of the rheumatic diseases.

[140]  Qizhi Zhang,et al.  Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. , 2014, Biomaterials.

[141]  Seiji Miura,et al.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[142]  J. Brotchie,et al.  Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit , 2013, Movement disorders : official journal of the Movement Disorder Society.

[143]  F. Ottery,et al.  Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy , 2013, Arthritis Research & Therapy.

[144]  V. Torchilin,et al.  Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety , 2013, Proceedings of the National Academy of Sciences.

[145]  Takahiro Nomoto,et al.  Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. , 2013, ACS nano.

[146]  S. Jon,et al.  Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[147]  J. Kopeček,et al.  Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats. , 2013, Biomaterials.

[148]  Peter Willett,et al.  What is a tutorial , 2013 .

[149]  N. Ohkohchi,et al.  NC‐6300, an epirubicin‐incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin , 2013, Cancer science.

[150]  Li Tang,et al.  Chain-shattering polymeric therapeutics with on-demand drug-release capability. , 2013, Angewandte Chemie.

[151]  Shirui Mao,et al.  Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. , 2013, ACS nano.

[152]  Z. Gu,et al.  The anti-tumor efficiency of poly(L-glutamic acid) dendrimers with polyhedral oligomeric silsesquioxane cores. , 2013, Biomaterials.

[153]  P. Stayton,et al.  pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. , 2013, ACS nano.

[154]  H. Frey,et al.  Poly(1,2-glycerol carbonate): A Fundamental Polymer Structure Synthesized from CO2 and Glycidyl Ethers , 2013 .

[155]  M. Grinstaff,et al.  Synthesis of atactic and isotactic poly(1,2-glycerol carbonate)s: degradable polymers for biomedical and pharmaceutical applications. , 2013, Journal of the American Chemical Society.

[156]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[157]  Amolkumar Karwa,et al.  Poly(ethylene oxide)-block-polyphosphester-based Paclitaxel Conjugates as a Platform for Ultra-high Paclitaxel-loaded Multifunctional Nanoparticles. , 2013, Chemical science.

[158]  Honggang Cui,et al.  Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. , 2013, Bioconjugate chemistry.

[159]  L. Thim,et al.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. , 2013, Blood.

[160]  P. Couvreur,et al.  Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization. , 2013, Angewandte Chemie.

[161]  Thommey P. Thomas,et al.  Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. , 2013, ACS nano.

[162]  J. Loo,et al.  A Heparin-Mimicking Polymer Conjugate Stabilizes Basic Fibroblast Growth Factor (bFGF) , 2013, Nature chemistry.

[163]  K. Uvdal,et al.  Multicolor fluorescent semiconducting polymer dots with narrow emissions and high brightness. , 2013, ACS nano.

[164]  J. Kopeček,et al.  Biological rationale for the design of polymeric anti-cancer nanomedicines , 2013, Journal of drug targeting.

[165]  Emma D. Deeks.  Certolizumab Pegol , 2013, Drugs.

[166]  R. Deberardinis,et al.  A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals , 2013 .

[167]  P. L. McCormack,et al.  Methoxy Polyethylene Glycol-Epoetin Beta , 2012, Drugs.

[168]  H. Ghandehari,et al.  Comparative pharmacokinetics of PAMAM-OH dendrimers and HPMA copolymers in ovarian tumor-bearing mice , 2012, Drug Delivery and Translational Research.

[169]  M. Vicent,et al.  Polyacetal-stilbene conjugates - The first examples of polymer therapeutics for the inhibition of HIF-1 in the treatment of solid tumours. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[170]  K. Ulbrich,et al.  HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[171]  X. Jing,et al.  Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[172]  M. Borad,et al.  A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors , 2012, Clinical Cancer Research.

[173]  O. Mishchenko,et al.  PUK24 Pharmacoeconomic Aspects of Use of Erythropoietin Drugs in Patients on Hemodialysis in Ukraine , 2012 .

[174]  Ching-Hui Huang,et al.  Biodegradable polydisulfide dendrimer nanoclusters as MRI contrast agents. , 2012, ACS nano.

[175]  Pascal Richette,et al.  Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents , 2012, Expert opinion on drug delivery.

[176]  Yingchao Han,et al.  Poly(2-oxazoline)s as polymer therapeutics. , 2012, Macromolecular rapid communications.

[177]  Eric D. Pressly,et al.  Poly[(ethylene oxide)-co-(methylene ethylene oxide)]: A hydrolytically-degradable poly(ethylene oxide) platform. , 2012, ACS macro letters.

[178]  J. Kopeček,et al.  Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis. , 2012, Biomaterials.

[179]  J. Lay,et al.  Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization. , 2012, Bioconjugate chemistry.

[180]  Yolonda L Colson,et al.  Biologically Responsive Polymeric Nanoparticles for Drug Delivery , 2012, Advanced materials.

[181]  Eun Seong Lee,et al.  Facile synthesis of multimeric micelles. , 2012, Angewandte Chemie.

[182]  C. van Nostrum,et al.  Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. , 2012, Angewandte Chemie.

[183]  M. Ribeiro,et al.  Biocompatible polyurea dendrimers with pH-dependent fluorescence. , 2012, Angewandte Chemie.

[184]  R. Autrata,et al.  Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II , 2012, European journal of ophthalmology.

[185]  David J Brayden,et al.  Direct peptide bioconjugation/PEGylation at tyrosine with linear and branched polymeric diazonium salts. , 2012, Journal of the American Chemical Society.

[186]  J. Janisse,et al.  Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model , 2012, Science Translational Medicine.

[187]  R. Langer,et al.  Photoswitchable Nanoparticles for Triggered Tissue Penetration and Drug Delivery , 2012, Journal of the American Chemical Society.

[188]  S. Brocchini,et al.  Site-specific PEGylation at histidine tags. , 2012, Bioconjugate chemistry.

[189]  J. Kopeček,et al.  Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. , 2012, Biomaterials.

[190]  Margaret S. Wu,et al.  FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents , 2012, Diabetes.

[191]  S. Caddick,et al.  Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents. , 2012, Journal of the American Chemical Society.

[192]  R. Iezzi,et al.  Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. , 2012, Biomaterials.

[193]  T. Mcclanahan,et al.  IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.

[194]  Seungpyo Hong,et al.  Dendrimer-mediated multivalent binding for the enhanced capture of tumor cells. , 2011, Angewandte Chemie.

[195]  Jin-Zhi Du,et al.  Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. , 2011, Journal of the American Chemical Society.

[196]  K. Ulbrich,et al.  Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[197]  Liangfang Zhang,et al.  Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. , 2011, Molecular pharmaceutics.

[198]  R. Duncan,et al.  The effect of dextrin-rhEGF on the healing of full-thickness, excisional wounds in the (db/db) diabetic mouse. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[199]  Jinming Gao,et al.  Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. , 2011, Angewandte Chemie.

[200]  A. Baas,et al.  FDA-approved poly(ethylene glycol)–protein conjugate drugs , 2011 .

[201]  G. Cotton,et al.  Recombinant protein hydrazides: application to site-specific protein PEGylation. , 2011, Bioconjugate chemistry.

[202]  B. E. Kimmel,et al.  Optimized clinical performance of growth hormone with an expanded genetic code , 2011, Proceedings of the National Academy of Sciences.

[203]  Bing‐Bing Yang,et al.  Pharmacokinetics and Pharmacodynamics of Pegfilgrastim , 2011, Clinical pharmacokinetics.

[204]  M. Gumbleton,et al.  Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[205]  J. Olson,et al.  Design of highly emissive polymer dot bioconjugates for in vivo tumor targeting. , 2011, Angewandte Chemie.

[206]  Deborah S. Goldberg,et al.  G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[207]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[208]  Justin Hanes,et al.  Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. , 2011, Angewandte Chemie.

[209]  S. Eliasof,et al.  CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development , 2011, Current bioactive compounds.

[210]  H. Klok,et al.  Arginine-specific modification of proteins with polyethylene glycol. , 2011, Biomacromolecules.

[211]  H. Ploegh,et al.  Sortase-catalyzed transformations that improve the properties of cytokines , 2011, Proceedings of the National Academy of Sciences.

[212]  A. Boddy,et al.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours , 2011, British Journal of Cancer.

[213]  Mark W Grinstaff,et al.  Biomedical applications of dendrimers: a tutorial. , 2011, Chemical Society reviews.

[214]  Shaoyi Jiang,et al.  Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. , 2011, Nature chemistry.

[215]  A. Ohtsu,et al.  Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors , 2010, Clinical Cancer Research.

[216]  S. Goldring,et al.  Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy , 2010, Arthritis research & therapy.

[217]  A. Chilkoti,et al.  In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation , 2010, Proceedings of the National Academy of Sciences.

[218]  A. S. Moses,et al.  Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.

[219]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[220]  Michael J Monteiro,et al.  Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. , 2010, Angewandte Chemie.

[221]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[222]  Anthony D. Keefe,et al.  Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.

[223]  Luiz A Canalle,et al.  Polypeptide-polymer bioconjugates. , 2010, Chemical Society reviews.

[224]  James R Baker,et al.  Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[225]  Maohong Fan,et al.  Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. , 2010, Journal of the American Chemical Society.

[226]  Jeffrey A. Cohen,et al.  Combination therapy in multiple sclerosis , 2010, The Lancet Neurology.

[227]  J. Kopeček,et al.  HPMA copolymers: origins, early developments, present, and future. , 2010, Advanced drug delivery reviews.

[228]  M. Vicent,et al.  Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. , 2010, Advanced drug delivery reviews.

[229]  J. Kopeček,et al.  Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. , 2010, Angewandte Chemie.

[230]  Y. Pei,et al.  Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. , 2010, Biomaterials.

[231]  James R. Baker,et al.  Protein Modification, Bioconjugation, and Disulfide Bridging Using Bromomaleimides , 2010, Journal of the American Chemical Society.

[232]  Robert Langer,et al.  Spatiotemporal controlled delivery of nanoparticles to injured vasculature , 2010, Proceedings of the National Academy of Sciences.

[233]  Andrew Tsourkas,et al.  Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. , 2010, Angewandte Chemie.

[234]  Krzysztof Matyjaszewski,et al.  Genetically encoded initiator for polymer growth from proteins. , 2010, Journal of the American Chemical Society.

[235]  Ruth Duncan,et al.  Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. , 2009, Advanced drug delivery reviews.

[236]  María J. Vicent,et al.  Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.

[237]  Ashutosh Chilkoti,et al.  Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumors after a single injection , 2009, Nature materials.

[238]  Robert Williams.  Discontinued drugs in 2008: oncology drugs , 2009, Expert opinion on investigational drugs.

[239]  Yi Jin,et al.  PAMAM-triamcinolone acetonide conjugate as a nucleus-targeting gene carrier for enhanced transfer activity. , 2009, Biomaterials.

[240]  A. Ray,et al.  Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[241]  D. Kerr,et al.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.

[242]  R. Satchi‐Fainaro,et al.  Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. , 2009, Angewandte Chemie.

[243]  F. Szoka,et al.  Dependence of pharmacokinetics and biodistribution on polymer architecture: effect of cyclic versus linear polymers. , 2009, Journal of the American Chemical Society.

[244]  Yolonda L Colson,et al.  Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. , 2009, Journal of the American Chemical Society.

[245]  Xiao-Wei Lu,et al.  Protein C-terminal modification through thioacid/azide amidation. , 2009, Bioconjugate chemistry.

[246]  A. Nesbitt,et al.  Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent , 2009 .

[247]  J. Kopeček,et al.  Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. , 2008, Molecular pharmaceutics.

[248]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[249]  C. Contag,et al.  Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters , 2008, Proceedings of the National Academy of Sciences.

[250]  B. Le Droumaguet,et al.  In situ ATRP-mediated hierarchical formation of giant amphiphile bionanoreactors. , 2008, Angewandte Chemie.

[251]  B. Sumerlin,et al.  Temperature-regulated activity of responsive polymer-protein conjugates prepared by grafting-from via RAFT polymerization. , 2008, Journal of the American Chemical Society.

[252]  S. Nilsson,et al.  Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. , 2008, Oncology reports.

[253]  R. D'Amato,et al.  An orally delivered small-molecule formulation with antiangiogenic and anticancer activity , 2008, Nature Biotechnology.

[254]  Jianjun Cheng,et al.  Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. , 2008, Angewandte Chemie.

[255]  L. Freitag,et al.  Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer , 2008, British Journal of Cancer.

[256]  Z. Guan,et al.  Living ring-opening polymerization of a carbohydrate-derived lactone for the synthesis of protein-resistant biomaterials. , 2008, Biomacromolecules.

[257]  F. Veronese,et al.  Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. , 2008, Advanced drug delivery reviews.

[258]  Haeshin Lee,et al.  Mussel-Inspired Surface Chemistry for Multifunctional Coatings , 2007, Science.

[259]  Jianjun Cheng,et al.  Anticancer Polymeric Nanomedicines , 2007 .

[260]  C. Barner‐Kowollik,et al.  Well-defined protein-polymer conjugates via in situ RAFT polymerization. , 2007, Journal of the American Chemical Society.

[261]  C. Barner‐Kowollik,et al.  In situ formation of protein-polymer conjugates through reversible addition fragmentation chain transfer polymerization. , 2007, Angewandte Chemie.

[262]  S. Kannan,et al.  Synthesis, characterization, and in vitro activity of dendrimer-streptokinase conjugates. , 2007, Bioconjugate chemistry.

[263]  B Ruozi,et al.  PLA/PLGA nanoparticles for sustained release of docetaxel. , 2006, International journal of pharmaceutics.

[264]  F. C. Dougherty,et al.  Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[265]  R. Bayer,et al.  GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. , 2006, Glycobiology.

[266]  Neel S. Joshi,et al.  N-terminal protein modification through a biomimetic transamination reaction. , 2006, Angewandte Chemie.

[267]  T. Mccarthy,et al.  Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. , 2005, Molecular pharmaceutics.

[268]  H. Maynard,et al.  Streptavidin as a macroinitiator for polymerization: in situ protein-polymer conjugate formation. , 2005, Journal of the American Chemical Society.

[269]  J. Choi,et al.  Poly(ethylene oxide sulfide): new poly(ethylene glycol) derivatives degradable in reductive conditions. , 2005, Biomacromolecules.

[270]  H. Ueno,et al.  Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.

[271]  Mark W Grinstaff,et al.  Dendritic molecular capsules for hydrophobic compounds. , 2003, Journal of the American Chemical Society.

[272]  M. Graham.  Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.

[273]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[274]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[275]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[276]  Kevin Pang,et al.  The further evolution of biotech , 2003, Nature Reviews Drug Discovery.

[277]  H. Sato,et al.  Enzymatic procedure for site-specific pegylation of proteins. , 2002, Advanced drug delivery reviews.

[278]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[279]  S. Pedder,et al.  Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. , 2002, Advanced drug delivery reviews.

[280]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[281]  D. Kerr,et al.  Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[282]  M. Grinstaff,et al.  Synthesis and Characterization of Poly(glycerol−succinic acid) Dendrimers , 2001 .

[283]  R. Tallarida,et al.  Drug synergism: its detection and applications. , 2001, The Journal of pharmacology and experimental therapeutics.

[284]  T. Ohno,et al.  Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells , 2001, Cancer Immunology, Immunotherapy.

[285]  P G Schultz,et al.  Expanding the Genetic Code of Escherichia coli , 2001, Science.

[286]  M. Grinstaff,et al.  Synthesis and characterization of polyether-ester dendrimers from glycerol and lactic acid. , 2001, Journal of the American Chemical Society.

[287]  H. Yamanaka,et al.  Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: longer survival with larger size tumors. , 2000, Urology.

[288]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[289]  D. Tzemach,et al.  Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes , 1999, Cancer.

[290]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[291]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[292]  E. Radwanski,et al.  Pharmacodynamics of subcutaneous recombinant human interleukin‐10 in healthy volunteers , 1997, Clinical pharmacology and therapeutics.

[293]  W. Velasquez,et al.  Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. , 1995, Formulary.

[294]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[295]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[296]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[297]  George R. Newkome,et al.  Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol , 1985 .

[298]  George R. Newkome,et al.  MICELLES. PART 1. CASCADE MOLECULES: A NEW APPROACH TO MICELLES. A (27)-ARBOROL , 1985 .

[299]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[300]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[301]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[302]  H. Ringsdorf.  Structure and properties of pharmacologically active polymers , 1975 .

[303]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[304]  Horst Jatzkewitz,et al.  An ein kolloidales Blutplasma-Ersatzmittel (Polyvinylpyrrolidon) gebundenes Peptamin (Glycyl-L-leucyl-mezcalin) als neuartige Depotform für biologisch aktive primäre Amine (Mezcalin) , 1955 .